Satellite solutions delivering information and communication technologies can help improve health in sub-Saharan Africa; this was the main conclusion of a dedicated telemedicine task force which met recently in Botswana. To make these solutions a reality, some short-term, concrete actions have been suggested in a pilot projects proposal.
The three most common forms of acute viral hepatitis in the United States ? hepatitis A, B and C ? declined dramatically between 1995 and 2005, with hepatitis A and B at the lowest levels ever recorded since the government began collecting surveillance data more than 40 years ago, according to the Centers for Disease Control and Prevention (CDC). Hepatitis B and C are diseases that can lead to liver cancer and death.
The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks.
AIDS Healthcare Foundation (AHF), the US? largest HIV/AIDS healthcare and prevention and education provider, which operates free AIDS treatment clinics in the US, Africa, Latin America/Caribbean and Asia, today excoriated US drug giant, Abbott Laboratories for its heartless decision to blacklist the country of Thailand by withdrawing its new drugs? applications from that country?s government review process?a move which in essence deprives Thailand and its citizens of access to any new Abbott medications.
The International Cricket Council (ICC) will team up with UNAIDS, UNICEF and the Caribbean Broadcast Media Partnership on HIV/AIDS at the ICC Cricket World Cup 2007 to highlight the situation of children and young people living with and affected by HIV.
A new method for analysis of retroviral proteins gives new opportunities to the development of novel retardants for HIV/Aids. The study, which was published in the March issue of PLoS Computational Biology, shows how to in a very exact way analyze the interaction of drug targets with small molecules.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced 60 U.S. and international institutions selected as HIV/AIDS Clinical Trials Units (CTUs) in a newly restructured system of six HIV/AIDS clinical research networks. NIAID expects to fund additional CTUs within the next several months, bringing the total to 73.
Twelve institutions today were named by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), as HIV/AIDS clinical trial units (CTUs) for the Microbicide Trials Network (MTN), a new HIV/AIDS clinical trials network established by NIAID last year.
Scientists hoping to find new treatments for one of the world?s most deadly infectious diseases say drugs used to treat common fungal infections may provide the answer.
Scientists have highlighted for the first time the plight of the growing number of older children and adolescents living with undiagnosed HIV and AIDS in Africa.